These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1296 related items for PubMed ID: 25127748

  • 41. Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C.
    Pattullo V, Ravindran NC, Mazzulli T, Wong DK, Heathcote EJ.
    J Viral Hepat; 2010 Dec; 17(12):834-8. PubMed ID: 20196800
    [Abstract] [Full Text] [Related]

  • 42. Peginterferon and ribavirin for treatment of recurrent hepatitis C disease in HCV-HIV coinfected liver transplant recipients.
    Terrault N, Reddy KR, Poordad F, Curry M, Schiano T, Johl J, Shaikh O, Dove L, Shetty K, Millis M, Schiff E, Regenstein F, Barnes D, Barin B, Peters M, Roland M, Stock P, HIVTR Investigators.
    Am J Transplant; 2014 May; 14(5):1129-35. PubMed ID: 24636466
    [Abstract] [Full Text] [Related]

  • 43. HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-alpha-2b/ribavirin.
    Moreno A, Bárcena R, García-Garzón S, Muriel A, Quereda C, Moreno L, Mateos ML, Fortún J, Martín-Dávila P, García M, Blesa C, Otón E, Moreno A, Moreno S.
    J Hepatol; 2005 Nov; 43(5):783-90. PubMed ID: 16084622
    [Abstract] [Full Text] [Related]

  • 44. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN.
    Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
    [Abstract] [Full Text] [Related]

  • 45. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
    Murata M, Furusyo N, Ogawa E, Mitsumoto F, Hiramine S, Ikezaki H, Takayama K, Shimizu M, Toyoda K, Kainuma M, Hayashi J.
    J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330
    [Abstract] [Full Text] [Related]

  • 46. Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
    Moreno L, Quereda C, Moreno A, Perez-Elías MJ, Antela A, Casado JL, Dronda F, Mateos ML, Bárcena R, Moreno S.
    AIDS; 2004 Jan 02; 18(1):67-73. PubMed ID: 15090831
    [Abstract] [Full Text] [Related]

  • 47. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.
    Inoue Y, Hiramatsu N, Oze T, Yakushijin T, Mochizuki K, Hagiwara H, Oshita M, Mita E, Fukui H, Inada M, Tamura S, Yoshihara H, Hayashi E, Inoue A, Imai Y, Kato M, Miyagi T, Hohsui A, Ishida H, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N.
    J Viral Hepat; 2010 May 02; 17(5):336-44. PubMed ID: 19678893
    [Abstract] [Full Text] [Related]

  • 48. [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].
    Husa P, Slesinger P, Stroblová H, Svobodník A, Husová L.
    Klin Mikrobiol Infekc Lek; 2008 Apr 02; 14(2):67-73. PubMed ID: 18756436
    [Abstract] [Full Text] [Related]

  • 49. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
    Crespo M, Esteban JI, Ribera E, Falco V, Sauleda S, Buti M, Esteban R, Guardia J, Ocaña I, Pahissa A.
    AIDS; 2007 Feb 19; 21(4):477-81. PubMed ID: 17301566
    [Abstract] [Full Text] [Related]

  • 50. Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a.
    Zhou YQ, Wang XH, Hong GH, Zhu Y, Zhang XQ, Hu YJ, Mao Q.
    J Viral Hepat; 2011 Aug 19; 18(8):595-600. PubMed ID: 21105968
    [Abstract] [Full Text] [Related]

  • 51. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
    Mira JA, García-Rey S, Rivero A, de los Santos-Gil I, López-Cortés LF, Girón-González JA, Téllez F, Márquez M, Merino D, Ríos-Villegas MJ, Macías J, Rivero-Juárez A, Pineda JA.
    Clin Infect Dis; 2012 Dec 19; 55(12):1719-26. PubMed ID: 22955435
    [Abstract] [Full Text] [Related]

  • 52. Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.
    Lim KB, Sima HR, Fiel MI, Khaitova V, Doucette JT, Chernyiak M, Ahmad J, Bach N, Chang C, Grewal P, Kim-Schluger L, Liu L, Odin J, Perumalswami P, Florman SS, Schiano TD.
    World J Gastroenterol; 2015 May 28; 21(20):6236-45. PubMed ID: 26034358
    [Abstract] [Full Text] [Related]

  • 53. Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study.
    Milazzo L, Caramma I, Mazzali C, Cesari M, Olivetti M, Galli M, Antinori S.
    J Antimicrob Chemother; 2010 Apr 28; 65(4):735-40. PubMed ID: 20118492
    [Abstract] [Full Text] [Related]

  • 54. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
    Peribañez-Gonzalez M, da Silva MH, Vilar FC, Seixas-Santos Nastri AC, Ferreira PA, Focaccia R, Mendes Correa MC.
    Ann Hepatol; 2013 Apr 28; 12(2):228-35. PubMed ID: 23396734
    [Abstract] [Full Text] [Related]

  • 55. Section 13. Short-course pretransplant antiviral therapy is a feasible and effective strategy to prevent hepatitis C recurrence after liver transplantation in genotype 2 patients.
    Lin CC, Kabiling C, Chen CL, Lin YH, Liu YW, Wang CC, Hu TH, Chiu KW.
    Transplantation; 2014 Apr 27; 97 Suppl 8():S47-53. PubMed ID: 24849835
    [Abstract] [Full Text] [Related]

  • 56. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.
    Pineda JA, Caruz A, Rivero A, Neukam K, Salas I, Camacho A, Palomares JC, Mira JA, Martínez A, Roldán C, de la Torre J, Macías J.
    Clin Infect Dis; 2010 Oct 01; 51(7):788-95. PubMed ID: 20804372
    [Abstract] [Full Text] [Related]

  • 57. Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients.
    Rallon NI, Lopez-Fernandez LA, Garcia MI, Benguria A, Fiorante S, Soriano V, Benito JM.
    AIDS; 2013 Mar 13; 27(5):687-96. PubMed ID: 23196939
    [Abstract] [Full Text] [Related]

  • 58. Patient's age modifies the impact of the proposed predictors of sustained virological response in chronic hepatitis C patients treated with PEG-interferon plus ribavirin.
    Elefsiniotis IS, Pavlidis C, Ketikoglou I, Koutsounas S, Scarmeas N, Pantazis KD, Moulakakis A, Tsianos EV.
    Eur J Intern Med; 2008 Jun 13; 19(4):266-70. PubMed ID: 18471675
    [Abstract] [Full Text] [Related]

  • 59. Sustained virological response and baseline predictors in HIV-HCV coinfected patients retreated with pegylated interferon and ribavirin after failing a previous interferon-based therapy: systematic review and meta-analysis.
    Basso M, Parisi SG, Mengoli C, Gentilini V, Menegotto N, Monticelli J, Nicolè S, Cruciani M, Palù G.
    HIV Clin Trials; 2013 Jun 13; 14(4):127-39. PubMed ID: 23924585
    [Abstract] [Full Text] [Related]

  • 60. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
    Braun DL, Rauch A, Aouri M, Durisch N, Eberhard N, Anagnostopoulos A, Ledergerber B, Müllhaupt B, Metzner KJ, Decosterd L, Böni J, Weber R, Fehr J, Swiss HIV Cohort Study.
    PLoS One; 2015 Jun 13; 10(7):e0133028. PubMed ID: 26176696
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 65.